[PDF] Top 20 Encuesta sobre Préstamos Bancarios en España : tercer trimestre de 2004

... in current IPF clinical trials, and is viewed by many as a surrogate, albeit unproven, for ...that therapies that improve symptoms without necessarily improving survival are also of value in the management ... See full document

... Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible disease of the lung that has no lasting option for therapy other than ...the current review is the possible use of ... See full document

... with idiopathic pulmonary fibrosis ...the current landscape of pharmacotherapy for IPF and highlights the prospects and potential of new therapies that are currently being pursued in ... See full document

... with drug therapy when initiated in asymptomatic ...adverse drug reactions in symptomatic or asymptomatic settings may influence long-term use of anti- fibrotic drugs and attenuate the possibility of any ... See full document

... Up to 25% of IPF patients and 40% of FPF patients exhibited the shortened telomeres, but less than half of these patients had the germline mutation in the TERT or TERC gene. The low frequency of these events suggested ... See full document

... through circulating proteins alone or in combination, specific genotypes of single nucleotide polymorphisms, or epigenetic biomarkers, will be crucial to develop better stratification tools for patients and drive ... See full document

... for pulmonary hypertension on dyspnoea and exercise capacity [23, 25 – 27]) have not shown positive results, and the duration of all RCTs has always been limited and often powered on surrogate ... See full document

... disease, pulmonary hypertension and lung cancer ...Regarding pulmonary hypertension, only a small proportion of AIR respondents (4%) would ‘‘regularly’’ treat pulmonary hypertension if present in ... See full document

... the current study was based on a scheme of one-time-point detection of the miRNAs without longitudinal measurements due to the clinical limitations, which may mask the relationship between the dynamic expressions ... See full document

... new drug for the treatment of IPF, with approval in Japan and further sales in ...this drug will greatly expand our understanding of pulmonary ... See full document

... diopathic pulmonary ibrosis (IPF) is a progressive and usually fatal lung disease that occurs in the 6th and 7th decades of life ...able therapies that appear to slow the rate of disease progression (3,4), ... See full document

... Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause with a median survival of 3 – 5 years after diagnosis [1]. Treatment of IPF aims at slowing or stopping the disease ... See full document

... apnea(OSA), pulmonary arterial ...PAH-specific drug such as sildenafil is an option for elderly ...described pulmonary infection is important comorbidity in IPF ...unilateral fibrosis have ... See full document

... years clinical trials have shown some benefit for different agents in the treatment of patients with IPF. The European IFIGENIA trial, investigating the combination of azathioprine and prednisone without or with ... See full document

... Abstract: Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung ...of pulmonary fibrosis involves multiple mechanisms, with abnormal behavior of alveolar epithelial ... See full document

... The current focus of IPF research is on the molecular genetics of pathologic events likely to occur at the epi- thelial-mesenchymal interface of the alveolus ...of pulmonary anatomical structural relation- ... See full document

... and therapies have improved for IPAH. Although treatments and therapies have improved disease progression and survival rate, there is still no definite ...all current FDA approved treatments and ... See full document

... be continuous occupancy of these receptors by their agonist [13, 14]. These findings have prompted the development of new endothelin receptor antagonists (ERAs), such as macitentan, which demonstrate enhanced tissue ... See full document

... Abstract: Idiopathic pulmonary fibrosis is a chronic fibrotic lung disease of unknown cause that occurs in adults and has a poor ...as novel therapies are ... See full document

... medical therapies of coronary artery disease are likely appropriate in most IPF patients with confirmed disease; however, coronary artery stenting with drug-eluting stents may not be appropriate in some IPF ... See full document